System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42355589 DOI: 10.3390/jcm15124421

Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study.

J Clin Med 15(12)

Authors: Loredana Deaconu, Oana Albai, Bogdan Timar, Adina Braha, Simona Popescu, Teodora Sorescu, Laura Gaita, Liana Iordan, Romulus Timar

Affiliations

  • Doctoral School of Medicine, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Second Department of Internal Medicine," Victor BabeÈ™" University of Medicine and Pharmacy, 300041 TimiÈ™oara, Romania.
  • Department of Diabetes, "Pius Brînzeu" Emergency County Hospital, 300723 Timisoara, Romania.
  • Center for Molecular Research in Nephrology and Vascular Disease, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

Abstract

Background and Objectives: Obesity and insulin resistance are major contributors to cardiometabolic disease and type 2 diabetes mellitus (T2DM). This study evaluated the real-world effects of semaglutide on metabolic parameters, body composition, and cardiometabolic risk factors in people with obesity, with and without T2DM, and explored predictors of treatment response. Materials and Methods: This retrospective longitudinal observational study included 70 adults with obesity (42 with T2DM and 28 without T2DM) treated with semaglutide according to current clinical guidelines. The primary outcomes were changes in body weight, waist circumference, fasting plasma glucose, and glycated hemoglobin (HbA1c). Secondary outcomes included changes in lipid profile, insulin resistance indices, inflammatory markers, hepatic parameters, and body composition assessed by bioelectrical impedance analysis (InBody770). Results: Semaglutide treatment was associated with significant reductions in body weight (-9 kg), waist circumference (-8 cm), HbA1c (-1.1%), systolic blood pressure (-7.5 mmHg), visceral fat area (-30.1 cm 2), and insulin resistance markers. Improvements in glycemic parameters were more pronounced in participants with T2DM. Skeletal muscle mass (SMM) was relatively preserved during treatment. Baseline HbA1c and visceral adiposity were independently associated with metabolic response. Conclusions: In this real-world observational cohort, semaglutide was associated with significant improvements in metabolic parameters, body composition, and cardiometabolic risk markers in people with obesity, with and without T2DM. Baseline metabolic characteristics may influence treatment response.

MeSH

Diabetes Mellitus, Insulin Resistance, Insulin, Body Composition, Body Weight, Obesity, Therapeutics, Waist Circumference, Diabetes Mellitus, Type 2, Semaglutide